Working in oncology is a hugely humbling and inspiring experience for all of us at Eisai. Underpinned by our human health care mission, our efforts to develop and find innovative therapies for hard-to-treat cancers is a responsibility that the whole oncology team across the EMEA region carries with deep respect and unwavering commitment.
Advances in cancer treatment have increased survival.1
Progress in cutting-edge research is increasing the overall understanding of cancer.1
Cancer mortality has decreased in nearly all European countries since 1995.1
More than 35 years of oncology research
Eisai first began its journey in oncology in 1987 with a small research group at the Tsukuba research laboratories in Japan; fast forward to the year 2000 and a 50-strong team specialising in oncology research was established. In 2006, Eisai focused on acquisitions to boost innovation and in 2018 began prioritising partnerships in addition to proprietary knowledge to improve innovation efficiency and accelerate progress. Since 2022, oncology research has been part of Eisai’s global Deep Human Biology Learning drug discovery organisation.
Understanding human biology
Having a deep understanding of human biology is the starting point for all our research and development including within oncology.
This helps to formulate and test drug discovery hypotheses, along with understanding the various biological changes that occur in human diseases.
Current disease areas
Eisai strives to give people living with cancer as much meaningful time as possible, particularly in areas of high unmet medical need. We currently operate in the key disease areas of thyroid cancer, kidney cancer, liver cancer, endometrial cancer and advanced breast cancer.
Our work in oncology is more than science - it’s about hope, compassion, and the belief that everyone deserves a chance at a healthier future.
A human health care (hhc) approach to oncology
By understanding what matters most to people living with cancer and their loved ones, Eisai continues to put them first, aiming to develop initiatives and take actions to support their unmet needs.
Find out more about our metastatic breast cancer initiative ‘FurtherMore’ here
Our endometrial cancer patient resource can be accessed here
1Comparator Report on Cancer in Europe 2025 – Disease Burden, Costs and Access to Medicines and Molecular Diagnostics, IHE Report, 2025:2.
